AstraZeneca First Dose Only 33% Effective Against Delta or Indian Variant – What’s Up With Pfizer – Economic, Financial & Business News

England, the country hardest hit by the coronavirus pandemic, warned that a single dose of AstraZeneca vaccine only provides 33% immunity against the Indian or Delta strain of Covid-19 within three weeks of application.

Shock in England: a well-known BBC presenter died after receiving the AstraZeneca vaccine

According to a study by the British Ministry of Health, the Pfizer has an effectiveness of 88% against Indian mutation after 2 doses. While that of AstraZeneca was 60% effective after both doses, but only 33% with the first.

Until now, only two cases of variant B.1.617.2 have been reported in Argentina, considered the most contagious and lethal detected so far and renamed Delta by WHO, the body that decided to stop using names to avoid stigmatizing the countries of origin of each variant.

What are the two variants of the coronavirus that appeared in Argentina and are of concern to the Government

The study, which was conducted between April and May, concluded that both vaccines, with their full immunization schedule, They are effective both with respect to symptomatic cases of the Indian variant and of the dominant variant in that country, called English or Kentish.

But he warned that, in the case of AstraZeneca, with a single dose, the effectiveness against symptomatic cases of the Indian mutation turns out to be only 33% at three weeks of application., compared to 50% against the English mutation.

Pfizer offered the government a contract for 13 million coronavirus vaccines

Britain’s health authorities had expressed their fear that the recent increase in the Indian variant will put at risk the Government’s so far successful plan to gradually exit the third lockdown, decreed in December 2020.

See also  COVID Vaccines Accelerated Research - Heilpraxis

The advancement of the Delta variant or Indian strain will delay the release from confinement, which began in December 2020.

Given the advancement of the Delta variant, the first Minister Boris Johnson and his cabinet are analyzing postponing the lack of refinement for two weeks, scheduled for June 21, coinciding with the beginning of summer in that hemisphere.

The advisor to the British government, Stephen Reicher, indicated that the execution of the next reopening measures on June 21 would be “reckless” and would represent “a serious risk to the population.”

, according to The Guardian newspaper.

Since the beginning of the pandemic, 4.5 million people tested positive in the UK, where there was already 127,800 dead.

Official data indicates that 72% of the UK adult population (40 million people) have already received at least one dose of a vaccine against the coronavirus; and that 42% (27 million) have already received both doses.

Boris Johnson, British Prime Minister

The Indian strain and vaccines

According to scientists, the difference in effectiveness between vaccines after two doses can be explained by the fact that the application of the full calendar of AstraZeneca it was later than for the Pfizer-BioNTech vaccine in the UK. Other data on antibody profiles show that more time is needed to reach maximum effectiveness with this vaccine.

Moscow’s Nikolai Gamaleya Center for Epidemiology and Microbiology announced in mid-May that it would study the effectiveness of Sputnik V before this strain. There are no official results yet, but there is hope: “The Russian vaccine, of course, could with this mutation, since, thanks to the booster vaccination, Sputnik V creates a very high reserve of neutralizing antibodies to the virus,” Russian health sources assured.

See also  Coronavirus live ticker: +++ 02:47 SPD General Secretary Klingbeil accuses Spahn of negligence +++

The Sinopharm, produced by the homonymous Chinese state laboratory, has an efficacy of 79.34% according to the first interim analysis of the results of the Phase 3 trial and the participants who received two doses produced a high level of antibodies against SARS CoV-2 at a rate of 99.52%. But there is no data on its effectiveness against the Delta variant.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.